Novartis Ag

University of Pennsylvania

Celeste Richardson

Qilong Wu

Reshma Singh

Hilmar Erhard Ebersbach

Michael C Milone

Jennifer Brogdon

David Jonathan Glass

Joan Mannick

Leon Murphy

Jiquan Zhang

Julia Jascur

Carl H June

Thomas Huber

Yongqiang Wang

Marco Ruella

Huijuan Song

Heather Huet

Eugene Choi

Gabriela Plesa

Saar Gill

Lai Wei

Qiumei Yang

Saad Kenderian

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Treatment of cancer using a CD33 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

Anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

Growing community of inventors

Cambridge, MA, United States of America

Celeste Richardson